2seventy Bio Inc (TSVT)

$4.96

-0.03

(-0.6%)▲

Live

Performance

  • $4.87
    $5.02
    $4.96
    downward going graph

    1.76%

    Downside

    Day's Volatility :2.94%

    Upside

    1.2%

    downward going graph
  • $1.54
    $6.40
    $4.96
    downward going graph

    69.05%

    Downside

    52 Weeks Volatility :76.02%

    Upside

    22.5%

    downward going graph

Returns

Period2seventy Bio IncSector (Health Care)Index (Russel 2000)
3 Months
9.67%
3.6%
0.0%
6 Months
7.31%
10.2%
0.0%
1 Year
33.42%
19.6%
0.0%
3 Years
-85.16%
16.8%
-23.0%

Highlights

Market Capitalization
256.5M
Book Value
$4.56
Earnings Per Share (EPS)
-3.06
Wall Street Target Price
8.25
Profit Margin
0.0%
Operating Margin TTM
-227.01%
Return On Assets TTM
-19.02%
Return On Equity TTM
-51.89%
Revenue TTM
44.1M
Revenue Per Share TTM
0.85
Quarterly Revenue Growth YOY
-75.1%
Gross Profit TTM
-183.5M
EBITDA
-176.6M
Diluted Eps TTM
-3.06
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-0.98
EPS Estimate Next Year
-0.46
EPS Estimate Current Quarter
-0.65
EPS Estimate Next Quarter
-0.41

Analyst Recommendation

Buy
    57%Buy
    42%Hold
    0
    0%Sell
Based on 14 Wall street analysts offering stock ratings for 2seventy Bio Inc(by analysts ranked 0 to 5 stars)
Based on 14 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
8
8
8
Hold
6
6
6
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 66.33%

Current $4.96
Target $8.25

Company Financials

FY18Y/Y Change
Revenue
54.6M
-
Net Income
-199.7M
-
Net Profit Margin
-365.98%
-
FY19Y/Y Change
Revenue
44.3M
↓ 18.84%
Net Income
-323.3M
↑ 61.87%
Net Profit Margin
-729.96%
↓ 363.98%
FY20Y/Y Change
Revenue
248.1M
↑ 460.15%
Net Income
-138.2M
↓ 57.27%
Net Profit Margin
-55.69%
↑ 674.27%
FY21Y/Y Change
Revenue
54.5M
↓ 78.03%
Net Income
-292.2M
↑ 111.49%
Net Profit Margin
-535.95%
↓ 480.26%
FY22Y/Y Change
Revenue
91.5M
↑ 67.81%
Net Income
-254.1M
↓ 13.03%
Net Profit Margin
-277.77%
↑ 258.18%
FY23Y/Y Change
Revenue
100.4M
↑ 9.72%
Net Income
-217.6M
↓ 14.39%
Net Profit Margin
-216.73%
↑ 61.04%
Q1 FY23Q/Q Change
Revenue
41.6M
↓ 25.91%
Net Income
-42.5M
↑ 83.53%
Net Profit Margin
-102.05%
↓ 60.85%
Q2 FY23Q/Q Change
Revenue
36.0M
↓ 13.39%
Net Income
-42.1M
↓ 0.91%
Net Profit Margin
-116.76%
↓ 14.71%
Q3 FY23Q/Q Change
Revenue
12.0M
↓ 66.62%
Net Income
-71.6M
↑ 70.21%
Net Profit Margin
-595.3%
↓ 478.54%
Q4 FY23Q/Q Change
Revenue
10.7M
↓ 11.22%
Net Income
-56.8M
↓ 20.68%
Net Profit Margin
-531.84%
↑ 63.46%
Q1 FY24Q/Q Change
Revenue
12.4M
↑ 16.39%
Net Income
-52.7M
↓ 7.3%
Net Profit Margin
-423.59%
↑ 108.25%
Q2 FY24Q/Q Change
Revenue
9.0M
↓ 27.89%
Net Income
24.9M
↓ 147.23%
Net Profit Margin
277.45%
↑ 701.04%
FY19Y/Y Change
Total Assets
314.9M
-
Total Liabilities
271.3M
-
FY20Y/Y Change
Total Assets
312.6M
↓ 0.74%
Total Liabilities
238.0M
↓ 12.26%
FY21Y/Y Change
Total Assets
759.7M
↑ 143.0%
Total Liabilities
399.9M
↑ 68.01%
FY22Y/Y Change
Total Assets
656.7M
↓ 13.56%
Total Liabilities
346.2M
↓ 13.42%
FY23Y/Y Change
Total Assets
565.4M
↓ 13.89%
Total Liabilities
310.1M
↓ 10.42%
Q1 FY23Q/Q Change
Total Assets
742.4M
↑ 13.06%
Total Liabilities
341.1M
↓ 1.47%
Q2 FY23Q/Q Change
Total Assets
705.7M
↓ 4.95%
Total Liabilities
338.2M
↓ 0.85%
Q3 FY23Q/Q Change
Total Assets
640.8M
↓ 9.2%
Total Liabilities
334.4M
↓ 1.13%
Q4 FY23Q/Q Change
Total Assets
565.4M
↓ 11.76%
Total Liabilities
310.1M
↓ 7.25%
Q1 FY24Q/Q Change
Total Assets
511.1M
↓ 9.62%
Total Liabilities
303.6M
↓ 2.1%
Q2 FY24Q/Q Change
Total Assets
517.9M
↑ 1.34%
Total Liabilities
283.1M
↓ 6.76%
FY18Y/Y Change
Operating Cash Flow
-146.2M
-
Investing Cash Flow
-50.8M
-
Financing Cash Flow
197.0M
-
FY19Y/Y Change
Operating Cash Flow
-208.0M
↑ 42.23%
Investing Cash Flow
-59.8M
↑ 17.59%
Financing Cash Flow
267.7M
↑ 35.87%
FY20Y/Y Change
Operating Cash Flow
-67.8M
↓ 67.4%
Investing Cash Flow
-22.3M
↓ 62.75%
Financing Cash Flow
90.1M
↓ 66.36%
FY21Y/Y Change
Operating Cash Flow
-207.0M
↑ 205.39%
Investing Cash Flow
15.4M
↓ 169.23%
Financing Cash Flow
354.9M
↑ 294.08%
FY22Y/Y Change
Operating Cash Flow
-237.1M
↑ 14.54%
Investing Cash Flow
11.7M
↓ 24.1%
Financing Cash Flow
166.2M
↓ 53.16%
Q1 FY23Q/Q Change
Operating Cash Flow
-49.1M
↓ 11.52%
Investing Cash Flow
44.8M
↓ 8520.68%
Financing Cash Flow
127.1M
↑ 54677.59%
Q2 FY23Q/Q Change
Operating Cash Flow
-32.7M
↓ 33.46%
Investing Cash Flow
-64.9M
↓ 244.83%
Financing Cash Flow
128.0K
↓ 99.9%

Technicals Summary

Sell

Neutral

Buy

2seventy Bio Inc is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
2seventy Bio Inc
2seventy Bio Inc
4.18%
7.31%
33.42%
-85.16%
-85.16%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-9.28%
10.06%
24.53%
74.0%
232.45%
Novo Nordisk A/s
Novo Nordisk A/s
-4.54%
-5.72%
21.59%
126.2%
349.01%
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
8.87%
102.98%
82.67%
44.83%
241.09%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
5.0%
20.77%
31.37%
158.16%
163.17%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
2seventy Bio Inc
2seventy Bio Inc
NA
NA
NA
-0.98
-0.52
-0.19
NA
4.56
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
26.41
26.41
1.37
44.9
0.17
0.08
NA
261.41
Novo Nordisk A/s
Novo Nordisk A/s
40.21
40.21
1.81
3.36
0.89
0.23
0.01
25.24
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
NA
NA
-0.49
-2.42
-15.01
0.02
NA
-0.02
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
32.84
NA
0.59
0.18
-0.03
0.13
NA
57.26
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
2seventy Bio Inc
2seventy Bio Inc
Buy
$256.5M
-85.16%
NA
0.0%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$110.0B
232.45%
26.41
32.04%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$529.8B
349.01%
40.21
34.84%
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
Buy
$38.1B
241.09%
NA
-3.11%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$128.7B
163.17%
32.84
-4.74%

Insights on 2seventy Bio Inc

  • Decreasing Revenue

    Revenue is down for the last 2 quarters, 12.43M → 8.96M (in $), with an average decrease of 27.9% per quarter

  • Increasing Net Profit

    Netprofit is up for the last 4 quarters, -71.63M → 24.87M (in $), with an average increase of 115.2% per quarter

  • Vs ALNY

    In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 82.9% return, outperforming this stock by 50.2%

Institutional Holdings

  • Kynam Capital Management, LP

    11.56%

  • Goldman Sachs Group Inc

    8.04%

  • BlackRock Inc

    7.11%

  • Vanguard Group Inc

    7.05%

  • Morgan Stanley - Brokerage Accounts

    6.35%

  • Madison Avenue Partners, LP

    4.98%

Company Information

we are an immuno-oncology cell therapy company focused on discovering and developing new therapies that truly disrupt the cancer treatment landscape. our name, 2seventy bio, is inspired by the maximum speed of translating human thought into action—270 miles per hour, and at 2seventy, we think in the language of time. with a deep understanding of cancer cell metabolism, genomics, and the human body’s immune response to tumor cells, we’re applying this knowledge and expertise to new classes of cellular therapies that are designed to “think” smarter and faster than cancer. it is this mindset that propels us forward because we know that time matters -- every day, every minute, every second -- to people living with cancer

Organization
2seventy Bio Inc
Employees
274
CEO
Mr. William D. Baird III, M.B.A.
Industry
Services

Discover More

FAQs